Background: Few studies have evaluated the association between pre-existing vitamin D deficiency (VDD) and incident TB. We assessed the impact of baseline vitamin D on TB disease risk.
Introduction
The global burden of tuberculosis (TB) remains high with approximately one-fourth to one-third of world's population infected with Mycobacterium Tuberculosis, and the World Health Organization (WHO) estimates 10 million people developed TB disease in 2017.
1 Concurrently, vitamin D deficiency (VDD) is a widespread problem, with reported adult prevalence of VDD ranging from 10% to 80% worldwide.
2, 3 Vitamin D is an important regulator of the immune system, 4 and in vitro studies have elucidated some of the mechanisms by which vitamin D plays a role in TB disease pathogenesis. 5, 6 The discovery that vitamin D activates cathelicidin-mediated killing of ingested mycobacteria in macrophages 5 has focused attention on the possibility that low vitamin D levels may contribute to TB disease progression.
Numerous observational studies have also documented lower serum vitamin D levels among TB patients compared to healthy controls, and prior meta-analyses investigating the association between vitamin D and TB have concluded that low vitamin D increases TB disease risk. [7] [8] [9] [10] However, most studies were cross-sectional studies and assessed vitamin D status after the diagnosis of active TB disease, rather than the impact of pre-existing vitamin D levels on the risk of progression to TB disease. Given that TB disease can induce profound metabolic abnormalities, it remains unclear whether vitamin D deficiency increases TB disease risk or whether TB disease leads to decreased serum vitamin D levels. Furthermore, prior studies evaluating the association between vitamin D and TB disease have used different cutoffs to categorize vitamin D levels or define vitamin D deficiency. [7] [8] [9] [10] Hence, it is challenging to determine whether there is a vitamin D threshold below which individuals are at risk of TB disease.
Here, we address the association of vitamin D levels on the risk of TB progression in two ways. We first report the results of a case control analysis nested in a prospective cohort study of household contacts of TB patients that we conducted in Lima, Peru. We next pool these data with those from other published prospective studies of vitamin D status and TB risk to conduct an individual participant data (IPD) metaanalysis synthesizing available evidence on the association between vitamin D levels and incident TB disease.
Methods Lima Cohort Study Ethics Statement
The study was approved by the Institutional Review Board of Harvard School of Public Health and the Research Ethics Committee of the National Institute of Health of Peru. All study participants or guardians provided written informed consent.
Study Setting and Population
Details of the study design and methods are described elsewhere 11, 12 and presented in the appendix (p 1). We enrolled a prospective cohort of household contacts (HHCs) of index TB patients in Lima, Peru between September 2009 and August 2012. We screened HHCs for pulmonary and extra-pulmonary TB disease at baseline and 2, 6, and 12 months after enrollment. We offered HIV testing and invited HHCs to provide a baseline blood sample. We classified HHCs as having incident secondary TB disease if they were diagnosed at least 15 days after index case enrollment and co-prevalent TB disease if they were diagnosed earlier.
We defined "cases" as HIV-negative HHCs with blood samples who developed incident secondary TB disease within one year of follow-up. For each case, we randomly selected four controls from among HHCs who were not diagnosed with TB disease, matching on gender and age by year.
At the end of follow up, we measured levels of total 25-(OH)D and retinol from stored blood samples.
Statistical Analysis
We defined vitamin D deficiency (VDD) as serum 25-(OH)D < 50 nmol/L, insufficiency as 50-75 nmol/L and sufficiency as > 75nmol/L. 13 We used univariate and multivariate conditional logistic regression models to evaluate the association between baseline VDD and risk of TB disease. Because we had previously observed that vitamin A deficiency increases TB risk in this cohort, 11 we also adjusted for vitamin A levels.
In sensitivity analyses, we restricted the analysis to HHCs diagnosed with incident TB at least 60 days after index patient enrollment and their matched controls. We also separately evaluated patients with microbiologically confirmed TB and their matched controls.
Systematic Review and IPD Meta-analysis Search Strategy and Data Sources
We conducted the systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA) guidelines. 14, 15 All studies included in the IPD metaanalysis received relevant institutional or country-specific ethics approval, and participants provided written or oral informed consent.
We searched the PubMed database (https://www.ncbi.nlm.nih.gov/pubmed) and EMBASE (https://www.embase.com) for all available studies up to December 31, 2017 on the association between vitamin D and incident tuberculosis disease. Supplementary table 1 provides details of our search strategy (appendix p 3).
Study Eligibility and Inclusion Criteria
We placed no restrictions on language. We included all prospective longitudinal studies of human participants at risk for TB if the study measured vitamin D levels in baseline blood samples obtained prior to a diagnosis of TB disease. Studies were included if they confirmed TB diagnosis by microbiological criteria or specified their clinical criteria for ascertaining TB disease and if they collected data on age and gender. We considered any clinical criteria for TB disease based on physician assessment, imaging studies or national guidelines and any laboratory method for assessing vitamin D levels. We did not require studies to control for possible confounders. We also considered reports from conference abstracts. We excluded the following: case reports; animal or in vitro studies; case-control or cross-sectional studies that measured vitamin D levels after TB diagnosis; studies that did not report vitamin D levels; studies of other diseases or non TB-related outcomes; studies of vitamin D and TB treatment outcomes or TB infection or TB immune reconstitution inflammatory syndrome (IRIS); reviews; meta-analyses; letters; editorials; and protocols.
Data Collection and Data Items
For each eligible study, two reviewers (OA and SC) independently performed full text reviews and extracted the following information: first author's last name, year of publication, study design and study aim, country of study, calendar years of study, length of follow up, number of incident TB cases, total number of subjects analyzed, criteria for diagnosing TB disease, laboratory method of vitamin D assay, method of categorizing vitamin D, assessment of HIV status, and covariates in multivariate analyses. Discrepancies were resolved by consensus.
We contacted all authors of the eligible studies identified from the systematic review and requested individual participant data. Lead investigators from all studies agreed to provide data, which were deidentified prior to transfer via email. We requested all available data on possible confounders of the association between vitamin D and TB disease including: age, gender, HIV status, weight, height, BMI, isoniazid preventive treatment, baseline tuberculin skin test result, TB disease history, and comorbid diseases. We also requested baseline vitamin D levels, incident TB disease status during study follow up, time from enrollment to TB diagnosis, and index case smear status if applicable. We reviewed data for consistency with published data and contacted authors for clarifications or missing information as needed.
Statistical Analysis
We conducted a one-step IPD meta-analysis combining data from the eligible studies and from the Perubased study. We used the unified criteria described above to define vitamin D deficiency (25-(OH)D < 50 nmol/L) and insufficiency (25-(OH)D 50-75 nmol/L). We further defined "very low" vitamin D levels as less than 25nmol/L. We considered datasets from each single-country study and from each country within a multi-country study as independent data sources. We used generalized linear mixed univariate and multivariate models to evaluate the association between baseline vitamin D status and risk of incident TB, including an indicator for each independent dataset as a random effect to account for within-study correlation. Multivariate models were adjusted for age, gender, BMI, and HIV. Given sparse data on other variables, we did not adjust for other potential confounders. We also separately evaluated the association between very low vitamin D levels, compared to sufficient levels, and TB disease risk. To determine whether the effect of vitamin D on incident TB differed by HIV status, we conducted a stratified analysis. In a sensitivity analysis, we restricted the main analysis to incident TB cases diagnosed at least 60 days after enrollment.
The IPD meta-analysis was conducted using the R package "lme4". 16 Role of the funding source The funding sources had no role in the study design, data collection, analysis, and interpretation, writing of the manuscript, and in the decision to submit for publication. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results

Lima Cohort Study
Among 6751 HIV-negative household contacts with baseline blood samples, 258 developed TB disease, 66 within 15 days of enrollment and 192 thereafter. Among these 192 secondary TB cases, 152 (79.1%) were microbiologically confirmed, and viable blood samples were available for analysis for 180 (93.8%) at the end of follow-up. Table 1 In the univariate analysis, household contacts with baseline vitamin D deficiency had a 54% increased risk of incident TB disease compared to those with sufficient levels though this was not statistically significant (95% CI 0.88 -2.71; p 0.13) [ Table 3 ]. Vitamin D insufficiency was associated with a smaller increase in risk of TB disease that was not significant (OR 1.23; 95% CI 0.72 -2.08; p 0.45). After adjusting for BMI categories, socioeconomic status, heavy alcohol consumption, tobacco use, isoniazid preventive therapy, TB history, comorbid disease, self-reported DM, index patient smear status, and season of sample collection, we found baseline vitamin D deficiency and insufficiency remained associated with an increased risk of incident TB disease that was not statistically significant (aOR 1.70; 95% CI 0.84 -3.46; p 0.14 and aOR 1.25; 95% CI 0.66 -2.40; p 0.50 respectively) [ Table 3 ]. When we further adjusted for vitamin A deficiency, we continued to find a non-significant increase in risk of TB disease among HHCs with vitamin D deficiency and sufficiency (aOR 1.60; 95% CI 0.76 -3.39; p 0.22 and aOR 1.21; 95% CI 0.62 -2.39; p 0.58 respectively).
Our conclusions did not differ from results of the main analysis when we restricted our analyses to cases (and matched controls) diagnosed at least 60 days after index patient enrollment or to microbiologically confirmed TB cases (Table 4) .
Systematic Review and IPD Meta-analysis
We identified 2689 citations from the initial PubMed and EMBASE searches. After screening titles and abstracts, we excluded 2678 articles because they were reviews, meta-analyses, letters, editorials or protocols (n = 1212), case reports (n = 515), studies of other diseases or other outcomes (n = 331), animal or in vitro studies (n = 247), case-control or cross-sectional studies that assessed vitamin D levels after TB disease diagnosis (n = 159), studies that did not measure vitamin D levels (n = 144), studies of TB treatment outcomes (n = 63), and studies of TB infection (n = 7) [ Figure 1 ]. We reviewed full texts of the remaining 11 articles 17-27 and further excluded three studies that assessed outcomes of TB-IRIS 24-26 and one study of TB infection with seasonality of TB.
27 Table 5 provides information about the seven eligible published studies [17] [18] [19] [20] [21] [22] [23] identified from the systematic review.
We obtained individual patient data from all eligible studies. One study provided patient data from a multi-site evaluation conducted in nine countries. 23 Six of the seven studies were prospective cohort or case-cohort studies 17,18,20-23 while one study was a nested case-control study. 19 The final combined dataset with our Lima cohort study included 3544 participants from 13 countries: Brazil, The Gambia, Haiti, India, Malawi, Pakistan, Peru, South Africa, Spain, Tanzania, Thailand, US, and Zimbabwe. We analyzed a total of 456 incident TB cases. The median time to TB diagnosis from enrollment was 152.0 days (IQR 44.0 -342.0 days). 
Discussion
The two analyses presented here provide consistent support for a modest dose dependent effect of vitamin D on future progression of TB disease across multiple studies conducted in diverse contexts. In the IPD, the association of low vitamin D levels with increased TB disease risk is especially strong among HIVpositive individuals whose risk of developing TB was more than four-fold higher for those with very low levels of vitamin D.
Our findings in these human studies support the role of vitamin D in TB disease that has been inferred from more fundamental research which has shown that vitamin D is an important regulator of innate immunity. 4 In vitro studies have enumerated multiple mechanisms by which VDD may influence pathogenesis of TB infection or disease. Vitamin D is implicated in the activation of cathelicidinmediated killing of ingested mycobacteria, 5 ,30 induction of IFN-γ-mediated activity in macrophages, 6 induction of reactive oxygen and nitrogen species, 31 stimulation of phagolysosome fusion in infected macrophages, 32 and inhibition of matrix metalloproteinases involved in the pathogenesis of cavitary pulmonary TB. 33 In addition to its impact on immunity, vitamin D status has been linked to human metabolic phenotypes that may be involved in the pathogenesis of TB. In vitro studies have demonstrated various ways by which vitamin D promotes insulin sensitivity, 34 and animal models have shown vitamin D deficiency impairs insulin secretion in pancreatic beta cells. 34, 35 Numerous observational studies have also found an inverse association between vitamin D levels and incident type 2 diabetes mellitus (DM). 34 Given DM is a well described risk factor for TB disease, 36, 37 vitamin D deficiency may also contribute to increased TB risk through its role in modifying risk of diabetes.
Two other lines of evidence point to a possible association between vitamin D and TB. First, multiple studies have reported an association between specific vitamin D receptor (VDR) polymorphisms and TB risk. 8, 38 Although it is not clear that the functional effect of these polymorphisms recapitulates the impact of low vitamin D levels, several studies show that the impact of VDR variants is stronger in the presence of VDD.
18,38,39 Secondly, TB incidence varies with season and peaks in summer months when vitamin D levels are highest. Some observers have postulated that low levels of sunshine, and hence vitamin D, in winter contribute to an increase in TB infection followed by a rise in TB disease incidence after a sixmonth lag.
27, [40] [41] [42] We also note previous studies have reported that low vitamin A is a strong predictor of incident TB disease.
23, 43 In a previous analysis of the Peru cohort, we found vitamin A deficiency conferred a 10-fold increase in TB disease risk, 11 and here we show that adjustment for vitamin A modestly attenuates the impact of vitamin D. Similarly, Tenforde et al. also reported that adjusting for vitamin A levels attenuated the effect of vitamin D on TB disease risk. 23 This raises the possibility that vitamin D levels correlate with other micronutrients implicated in the pathogenesis of TB and these micronutrients may be more potent mediators of increased TB risk.
Although we did not detect a statistically significant interaction between vitamin D levels and HIV status, our findings raise the possibility that the effect of low vitamin D on TB risk may be more pronounced among HIV-positive patients. Studies have shown that among HIV-infected individuals, VDD is associated with deleterious immune activation, 44 lower CD4 counts, 44, 45 higher viral loads, 44 and accelerated HIV disease progression. 44, 46 Thus, VDD may exacerbate existing immune dysregulation in HIV infection to further increase TB risk or low vitamin D levels may reflect severity of HIV-related immunosuppression. In vitro studies have also demonstrated vitamin D restricts mycobacterial growth in the presence of HIV infection. 47 A clinical trial is currently underway to evaluate the efficacy of vitamin D supplementation in preventing incident TB among adults living with HIV in Tanzania; 52 the results may help clarify role of vitamin D in HIV-associated TB disease. We also plan to measure inflammatory markers in the Peru cohort to explore any association between VDD and immune dysregulation.
We considered several possible explanations for why we did not detect a significant association between VDD and TB risk in the Peru cohort study, despite its relatively large size. First, since TB incidence is highest in summer 41, 42 and HHCs were recruited at the time the index case was diagnosed, they are more likely to have been recruited and assessed when their vitamin D levels were highest. If levels later fell and this fall precipitated TB progression, this would not have been detected. Secondly, the VDR variants are heterogeneously distributed in different populations and may modify the effect of vitamin D on TB risk. We did not measure VDR variants in Peru and are therefore unable to assess the prevalence of different VDR genotypes in this cohort. The Peru study is also limited by the relatively short (one year) period of follow-up and the fact that it was only powered to detect a three-fold or greater difference in TB incidence among people with VDD.
Our IPD meta-analysis also has some important limitations. Firstly, many possible confounding covariates were not measured across all the studies, and we were therefore unable to account for all possible factors such as baseline infection status, other micronutrient levels and comorbidities that might be associated with both VDD and TB risk. Secondly, although we only examined prospective studies of incident TB disease, the included studies were all observational, and we cannot exclude the possibility that participants had early, undiagnosed TB at baseline that lowered vitamin D levels. Although we addressed this by conducting a sensitivity analysis excluding incident TB cases diagnosed less than 60 days after enrollment, the smaller number of incident cases diagnosed after 60 days reduced the power to detect a statistically significant association. We also cannot exclude the possibility of publication bias if studies with non-significant findings on the link between vitamin D and incident TB have remained unpublished. We did not construct a funnel plot to assess publication bias because we analyzed fewer than ten studies, which used different methods to categorize vitamin D levels and therefore provided effect estimates are not directly comparable. During our systematic review, we attempted to address this by considering data reported from meeting abstracts and none met our inclusion criteria.
In conclusion, in our meta-analysis of prospective studies, we found that vitamin D deficiency was associated with increased risk of incident TB disease. This finding suggests that vitamin D status is a predictor of incident TB disease; however, randomized control trials are needed to determine whether vitamin D supplementation can reduce the risk of developing TB disease. Future research should also elucidate the mechanisms by which low vitamin D may affect TB risk. 2 ). For children and adolescents < 20 years, we used World Health Organization (WHO) age and gender-specific BMI z-scores tables to classify those with BMI zscore < -2 as underweight and those with z-score > 2 as overweight. ‡ We used principal components analysis of housing asset (housing type, number of rooms, water supply, sanitation facilities, lighting, composition of exterior walls and floor and roof materials) weighted by household size to compute a socioeconomic status score. 1.00 1.00 P trend = 0.02 P trend = 0.03 * Adjusted for age and gender due to presence of age and gender matched case control study in the combined dataset † Adjusted for age, gender, BMI categories and HIV status ‡ N = 3164 § N = 2915 
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